Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis

Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis

Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.

Vertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement

Vertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement

Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.